

Amal Therapeutics to publish R&D findings in Cancer Research

Geneva, Switzerland, June 26, 2015 – Amal Therapeutics announced today that part of its recent research findings about a new type of recombinant protein cancer vaccines, will be available on-line on the Cancer Research website on Friday June 26, 2015. (Link below)

http://cancerres.aacrjournals.org/content/early/2015/06/25/0008-5472.CAN-14-3017.full.pdf+html

The publication underlines the value of a novel immunotherapy class able to simultaneously inducing multi-epitopic immunity, T helper functions and immunologic memory. The article shows that vaccines tested are able to significantly prolonged survival in three robust tumor models. "The results published are demonstrating the proof of concept and showing the strength of Amal's platform for the development of potent, safe and efficacious cancer vaccines", said Dr. Derouazi, CEO of Amal Therapeutics. "Having the outcome of our work published in Cancer Research is a great success and a value recognition of the scientific approach taken since Amal's incorporation in 2012", added Dr. Derouazi.

About Cancer Research

Cancer Research [Print ISSN: 0008-5472; Online ISSN: 1538-7445] is the most frequently cited cancer journal in the world. The journal publishes original studies, reviews, and opinion pieces offering significance and broad impact to a diverse audience spanning basic, preclinical, clinical, prevention, and epidemiologic research. Cancer Research is published twice a month, one volume/year, by The American Association for Cancer Research, Inc. (AACR), http://cancerres.aacrjournals.org, cancerres@aacr.org

About Amal Therapeutics

Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. www.amaltherapeutics.com, contact@amaltherapeutics.com